Study identifier:16557
ClinicalTrials.gov identifier:NCT02972658
EudraCT identifier:2016-003440-36
CTIS identifier:N/A
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Alzheimer's disease
Phase 3
No
Lanabecestat
All
421
Interventional
55 Years +
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2019 by AstraZeneca
AstraZeneca
Eli Lilly and Company
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.
Study AZFD was designed to be integrated with 104-week study AZES to form a Delayed-Start study (Study AZES-FD). Study AZES-FD was to be used to test the hypothesis that participants originally randomized to receive placebo in the double-blind feeder study AZES and switched to LY3314814 at the start of study AZFD did not "catch up" on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) at Week 26 of study AZFD to participants originally randomized to receive LY3314814 in the double-blind feeder study.
Location
Location
Sarasota, FL, United States, 34243
Location
Dijon, France, 21079
Location
Marseille, Cedex 05, France, 13385
Location
Hasselt, Limburg, Belgium, 3500
Location
Brussels, Belgium, 1200
Location
Seogu, Busan, Republic of Korea, 49201
Location
Warszawa, Poland, 01-697
Location
Kurashiki, Okayama, Japan, 701-0192
Arms | Assigned Interventions |
---|---|
Experimental: AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 |
Experimental: AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 |
Experimental: AZES Placebo/AZFD Lanabecestat 20 mg Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 |
Experimental: AZES Placebo/AZFD Lanabecestat 50 mg Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.